merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Company profile
Ticker
MRUS
Exchange
Website
CEO
Sven Lundberg
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Merus B.V.
SEC CIK
MRUS stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
PRE 14A
Preliminary proxy
29 Mar 24
8-K
Entry into a Material Definitive Agreement
6 Mar 24
S-8
Registration of securities for employees
28 Feb 24
S-3ASR
Automatic shelf registration
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Entry into a Material Definitive Agreement
11 Aug 23
424B5
Prospectus supplement for primary offering
11 Aug 23
Latest ownership filings
SC 13G
INCYTE CORP
25 Mar 24
SC 13G/A
FEDERATED HERMES, INC.
6 Mar 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
SC 13G
SAMLYN CAPITAL, LLC
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Flynn James E
12 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
FEDERATED HERMES, INC.
18 Jan 24
4
Harry Shuman
20 Dec 23
4
Peter B. Silverman
18 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 242.62 mm | 242.62 mm | 242.62 mm | 242.62 mm | 242.62 mm | 242.62 mm |
Cash burn (monthly) | (no burn) | (no burn) | 12.79 mm | 16.17 mm | 9.18 mm | 11.36 mm |
Cash used (since last report) | n/a | n/a | 87.97 mm | 111.23 mm | 63.12 mm | 78.17 mm |
Cash remaining | n/a | n/a | 154.64 mm | 131.39 mm | 179.49 mm | 164.44 mm |
Runway (months of cash) | n/a | n/a | 12.1 | 8.1 | 19.6 | 14.5 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 117 |
Opened positions | 15 |
Closed positions | 15 |
Increased positions | 48 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 1.11 tn |
Total shares | 62.37 mm |
Total puts | 119.60 k |
Total calls | 51.20 k |
Total put/call ratio | 2.3 |
Largest owners | Shares | Value |
---|---|---|
Commodore Capital | 4.43 mm | $104.41 bn |
INCY Incyte | 4.00 mm | $91.66 mm |
Deerfield Management | 3.88 mm | $91.42 bn |
Samlyn Capital | 3.26 mm | $76.79 bn |
Biotechnology Value Fund L P | 2.98 mm | $0.00 |
FHI Federated Hermes Inc - Ordinary Shares | 2.89 mm | $68.04 bn |
BVF | 2.75 mm | $64.90 bn |
Wellington Management | 2.74 mm | $64.50 bn |
Flynn James E | 2.38 mm | $0.00 |
Bay City Capital | 2.11 mm | $50.26 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Dec 23 | Harry Shuman | Common Shares | Sell | Dispose S | No | No | 26.68 | 115 | 3.07 k | 7,002 |
15 Dec 23 | Silverman Peter B. | Common Shares | Sell | Dispose S | No | No | 25 | 22,386 | 559.65 k | 0 |
15 Dec 23 | Silverman Peter B. | Common Shares | Option exercise | Acquire M | No | No | 0 | 1,286 | 0.00 | 22,386 |
15 Dec 23 | Silverman Peter B. | Common Shares | Option exercise | Acquire M | No | No | 0 | 21,100 | 0.00 | 21,100 |
15 Dec 23 | Silverman Peter B. | Share Option Common Shares | Option exercise | Dispose M | No | No | 12.37 | 1,286 | 15.91 k | 0 |
15 Dec 23 | Silverman Peter B. | Share Option Common Shares | Option exercise | Dispose M | No | No | 11.16 | 21,100 | 235.48 k | 0 |
8 Dec 23 | Harry Shuman | Common Shares | Sell | Dispose S | No | No | 24.44 | 250 | 6.11 k | 7,117 |
1 Dec 23 | Harry Shuman | Common Shares | Sell | Dispose S | No | Yes | 24.58 | 575 | 14.13 k | 7,367 |
1 Dec 23 | Harry Shuman | Common Shares | Option exercise | Acquire M | No | No | 0 | 2,500 | 0.00 | 7,942 |
1 Dec 23 | Harry Shuman | Restricted Share Unit Common Shares | Option exercise | Dispose M | No | No | 0 | 2,500 | 0.00 | 5,000 |
News
Needham Reiterates Buy on Merus, Maintains $66 Price Target
11 Apr 24
Merus Presents Preclinical Data Demonstrating Efficacy Of Zeno In Cancer Models With High NRG1 Expression At The AACR Annual Meeting 2024
8 Apr 24
Truist Securities Initiates Coverage On Merus with Buy Rating, Announces Price Target of $69
28 Mar 24
Needham Maintains Buy on Merus, Raises Price Target to $66
7 Mar 24
Needham Maintains Buy on Merus, Raises Price Target to $65
4 Mar 24
Press releases
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
8 Apr 24
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
5 Mar 24
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
4 Mar 24
Merus to Participate in Upcoming Investor Conferences
31 Jan 24